X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (467) 467
Publication (18) 18
Newsletter (12) 12
Book Review (11) 11
Newspaper Article (8) 8
Book Chapter (2) 2
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (399) 399
male (240) 240
female (235) 235
glycopyrrolate (221) 221
index medicus (199) 199
glycopyrrolate - adverse effects (186) 186
glycopyrrolate - administration & dosage (170) 170
middle aged (159) 159
adult (151) 151
glycopyrrolate - therapeutic use (150) 150
aged (111) 111
pulmonary disease, chronic obstructive - drug therapy (110) 110
treatment outcome (109) 109
double-blind method (108) 108
muscarinic antagonists - adverse effects (95) 95
respiratory system (92) 92
muscarinic antagonists - administration & dosage (89) 89
lung diseases, obstructive (81) 81
obstructive pulmonary-disease (80) 80
administration, inhalation (76) 76
anesthesiology (76) 76
muscarinic antagonists - therapeutic use (76) 76
tiotropium (75) 75
copd (74) 74
bronchodilator agents - administration & dosage (71) 71
adolescent (67) 67
bronchodilator agents - adverse effects (65) 65
pulmonary disease, chronic obstructive - physiopathology (65) 65
double-blind (61) 61
glycopyrronium (58) 58
chronic obstructive pulmonary disease (57) 57
efficacy (57) 57
time factors (57) 57
care and treatment (54) 54
pharmacology & pharmacy (54) 54
heart rate - drug effects (53) 53
safety (53) 53
drug therapy (51) 51
glycopyrrolate - pharmacology (49) 49
anesthesia (48) 48
atropine (48) 48
pulmonary disease, chronic obstructive - diagnosis (47) 47
severity of illness index (47) 47
indacaterol (46) 46
child (43) 43
research (43) 43
atropine - adverse effects (42) 42
diseases of the respiratory system (42) 42
dosage and administration (42) 42
drug combinations (42) 42
cross-over studies (39) 39
indans - administration & dosage (39) 39
quinolones - administration & dosage (39) 39
drug therapy, combination (38) 38
drug administration schedule (37) 37
indans - adverse effects (37) 37
quinolones - adverse effects (37) 37
surgery (37) 37
bronchodilator agents - therapeutic use (36) 36
dose-response relationship, drug (36) 36
forced expiratory volume (36) 36
international journal of chronic obstructive pulmonary disease (36) 36
lung - physiopathology (36) 36
children (35) 35
lung - drug effects (35) 35
adrenergic beta-2 receptor agonists - administration & dosage (33) 33
child, preschool (33) 33
management (32) 32
sialorrhea - drug therapy (32) 32
original research (30) 30
animals (29) 29
adrenergic beta-2 receptor agonists - adverse effects (27) 27
formoterol (27) 27
analysis (26) 26
atropine - therapeutic use (26) 26
clinical trials (26) 26
health aspects (26) 26
hyperhidrosis (26) 26
infant (26) 26
medical research (26) 26
pediatrics (26) 26
prospective studies (26) 26
young adult (26) 26
aged, 80 and over (25) 25
blood pressure - drug effects (25) 25
hyperhidrosis - drug therapy (25) 25
lama (25) 25
qva149 (25) 25
atropine - administration & dosage (24) 24
neostigmine - adverse effects (24) 24
placebo (24) 24
preanesthetic medication (24) 24
bradycardia - chemically induced (23) 23
complications and side effects (23) 23
medicine, general & internal (23) 23
pharmacokinetics (23) 23
glycopyrrolate - analogs & derivatives (22) 22
glycopyrrolate - pharmacokinetics (22) 22
indans - therapeutic use (22) 22
medicine, experimental (22) 22
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 23, pp. 2222 - 2234
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 1, pp. 51 - 60
Journal Article
International Journal of COPD, ISSN 1176-9106, 06/2015, Volume 10, pp. 1015 - 1026
Background: The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one or more bronchodilators... 
Clinical trial | agonists | Long-acting muscarinic antagonist | Long-acting β | COPD | clinical trial | COST-EFFECTIVENESS | SAFETY | INHALED CORTICOSTEROIDS | SALMETEROL | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | PRIMARY-CARE | FLUTICASONE PROPIONATE | RESPIRATORY SYSTEM | DOUBLE-BLIND | TIOTROPIUM | long-acting beta-agonists | long-acting muscarinic antagonist | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Spirometry | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Recovery of Function | Fluticasone-Salmeterol Drug Combination - adverse effects | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Surveys and Questionnaires | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Glycopyrrolate - therapeutic use | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Glycopyrrolate - analogs & derivatives | Fluticasone-Salmeterol Drug Combination - administration & dosage | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Drug therapy, Combination | Comparative analysis | Drug therapy | Methods | Bronchodilator agents
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 3, pp. 199 - 209
Journal Article
Dermatology Online Journal, ISSN 1087-2108, 2016, Volume 22, Issue 10
Hyperhidrosis, or abnormally increased sweating, is a condition that may have a primary or secondary cause. Usually medication- induced secondary hyperhidrosis... 
Craniofacial | Glycopyrrolate | Hyperhidrosis | Compensatory | Glycopyrrolate - adverse effects | Hyperhidrosis - drug therapy | Hyperhidrosis - chemically induced | Deprescriptions | Mandelic Acids - therapeutic use | Humans | Muscarinic Antagonists - adverse effects | Adult | Female | Treatment Outcome | Muscarinic Antagonists - therapeutic use
Journal Article
Thorax, ISSN 0040-6376, 04/2015, Volume 70, Issue 4, pp. 311 - 319
Background QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the... 
INDACATEROL | THERAPY | RESPIRATORY SYSTEM | DAILY SALMETEROL | DUAL BRONCHODILATION | LUNG-FUNCTION | DOUBLE-BLIND | EXACERBATIONS | OUTCOMES | GLYCOPYRRONIUM | HEALTH-STATUS | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Ethanolamines - adverse effects | Formoterol Fumarate | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Ethanolamines - administration & dosage | Indans - therapeutic use | Vital Capacity - drug effects | Quinolones - adverse effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Scopolamine Derivatives - administration & dosage | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Scopolamine Derivatives - therapeutic use | Scopolamine Derivatives - adverse effects | Tiotropium Bromide | Glycopyrrolate - adverse effects | Double-Blind Method | Drug Administration Schedule | Glycopyrrolate - therapeutic use | Treatment Outcome | Glycopyrrolate - analogs & derivatives | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Quality of Life | Adrenergic beta-2 Receptor Agonists - administration & dosage | Ethanolamines - therapeutic use | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Care and treatment | Analysis | Formoterol | Indacaterol | Dosage and administration | Diagnosis | Quality of life | 1506 | Chronic Obstructive Pulmonary Disease | COPD Pharmacology
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2013, Volume 107, Issue 10, pp. 1558 - 1567
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2014, Volume 108, Issue 4, pp. 584 - 592
Summary Introduction QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2 -agonist indacaterol... 
Pulmonary/Respiratory | QVA149 | Tiotropium | Chronic obstructive pulmonary disease | Exercise | Hyperinflation | PLACEBO | CARDIAC & CARDIOVASCULAR SYSTEMS | DAILY NVA237 | EFFICACY | SAFETY | BRONCHODILATION | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | TWICE-DAILY SALMETEROL | ONCE-DAILY INDACATEROL | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Exercise Tolerance - drug effects | Indans - therapeutic use | Lung Volume Measurements | Vital Capacity - drug effects | Quinolones - adverse effects | Spirometry - methods | Quinolones - therapeutic use | Adult | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Scopolamine Derivatives - therapeutic use | Tiotropium Bromide | Glycopyrrolate - adverse effects | Double-Blind Method | Drug Administration Schedule | Glycopyrrolate - therapeutic use | Treatment Outcome | Glycopyrrolate - analogs & derivatives | Cross-Over Studies | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Aged | Pulmonary Disease, Chronic Obstructive - drug therapy | Medicine, Experimental | Medical research | Lung diseases, Obstructive | Confidence intervals | Drug therapy
Journal Article
Respiratory Research, ISSN 1465-9921, 07/2017, Volume 18, Issue 1, pp. 140 - 9
Background: Dual bronchodilation combining a long-acting beta(2)-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) is the preferred choice of... 
Indacaterol/glycopyrronium | Open-label | Chronic obstructive pulmonary disease | Dual bronchodilation | Direct switch | INDACATEROL | MULTICENTER | QVA149 | SALMETEROL-FLUTICASONE | SALMETEROL/FLUTICASONE | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | DOUBLE-BLIND | EXACERBATIONS | TIOTROPIUM | GLYCOPYRRONIUM | Indans - adverse effects | Prospective Studies | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Recovery of Function | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Patient Safety | Adult | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Dyspnea - diagnosis | Europe | Risk Factors | Treatment Outcome | Dyspnea - physiopathology | Lung - physiopathology | Disease Progression | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Quality of Life | Adrenergic beta-2 Receptor Agonists - administration & dosage | Dyspnea - drug therapy | Aged | Drug Substitution | Health Status | Pulmonary Disease, Chronic Obstructive - drug therapy | Complications and side effects | Lung diseases, Obstructive | Corticosteroids | Patient outcomes | Dosage and administration | Indacaterol | Drug therapy, Combination | Research | Drug therapy | Performance evaluation | Bronchodilation | Drugs | Medical research | Gold | Respiratory function | Acetylcholine receptors (muscarinic) | Control methods | Lung diseases | Medical services | Clinical trials | Disease control | Patients | Primary care | Randomization | Dyspnea | Motivation | Obstructive lung disease | Clinical medicine | Safety | Respiration | glycopyrronium
Journal Article